WILMINGTON, Del. - The U.S. Food and Drug Administration (FDA) has granted approval to AstraZeneca (NASDAQ:AZN)'s CALQUENCE® ...

However, AstraZeneca and its partner Daiichi Sankyo withdrew their application for marketing authorization in the European Union for their drug datopotamab deruxtecan, intended to treat a form of ...

AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan ... in oncology with the ambition to provide cures for cancer in every form, following the science to ...

The drug candidate is administered orally in the form of a film-coated tablet ... in the UK and around the world. AstraZeneca submitted a compliant application for the clinical study to the ...

IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

While the deals done this week are important for the future direction of the industry – US company Gilead (US:GILD) inked the biggest, paying up to $1.7bn for Leo Pharma’s range of pre-clinical ...

I hope that it does this through competition policy (such as restoration of the Trump 45 New Madison Approach to patent licensing); through elimination of the threat of unwarranted application of ...

Gammaglobulin (IVIg) – trials have proven the effectiveness of this form of treatment ... positive topline results in December 2023. AstraZeneca/Alexion completed a Phase 3 trial of SOLIRIS ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

A next-generation form of chemotherapy from AstraZeneca and Daiichi Sankyo has won Food and Drug Administration authorization for a form of breast cancer, the first U.S. approval for a drug for ...